Menu
Synergy in Action

Suicidal Ideation and Behavior Assessment Working Group Activity / Deliverables

Chairs: Larry Alphs, MD, PhD; Phillip Chappell, MD, MBA; Michelle Stewart, PhD
Potentially reforming with new objective (3/2017)
Current Activity:  Developing multiple publications from the 2015 Consensus meeting.
SIB Consensus Meeting subcommittee  WORKING GROUP PAGE
Publications:
Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus Meeting
J Clin Psychiatry 2017;78(6):e638–e647
Innovations in Clinical Neuroscience: October 2014 Prospective Assessment of Suicidal Ideation and Behavior: An Internet Survey of Pharmaceutical Sponsor Practices
Innovations in Clinical Neuroscience: May-June 2013 (ISCTM Supplement #1) (Study Site Experiences)
Activity History:
Poster presented at ISCTM 2016 Autumn Conference
Consensus Meeting on Methodological Considerations for Suicide Assessment and Clinical Trial Design 17-18 November 2015
10th Annual Meeting Poster Presentation: Prospective Suicidal Ideation and Behavior Assessment:  An Internet Survey of Pharmaceutical Sponsor Practices
Working Group Dinner, 17 February 2014, Washington DC
Presentation; Report Back Summary
2013 Autumn Conference – 30 September 2013, Philadelphia, PA
Working Group Dinner, 19 February 2013, The Fairmont, Washington, DC
Plenary Session at 2013 Annual Scientific Meeting – Suicidal Ideation and Behavior: Methodological and Technical Challenges
Manuscript completed – pending publication in Innovations in Clinical Neuroscience
ISCTM Comment on (2012) FDA Draft Guidance for Industry “Suicidality: Prospective Assessment of Occurrence in Clinical Trials
21 February 2012 SIB Working Group Session Plenary Report Back
Poster presented at NCDEU 2012

Poster presented at ISCTM 2011 Autumn Conference
Summary of working group conducted at February 2011 7th Annual Scientific Meeting, Washington, D.C.
ISCTM Comment on (2010)FDA Draft Guidance for Industry “Suicidality: Prospective Assessment of Occurrence in Clinical Trials